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Background. Millions of people are infected with hepatitis C virus (HCV) worldwide and 30% spontaneously clear the infection.
Reasons for HCV clearance without antiviral treatment are not well understood. Methods. Blood was collected for DNA analysis
from patients with chronic HCV infection or evidence of spontaneous clearance. To overcome anticipated limitations of small
sample size, primary analyses consisted of a candidate gene analysis of 12 preselected genes based on known association with host
immunologic response to HCV infection. To further reduce the impact of multiple testing on power, a single likelihood ratio test
was conducted for each gene using all associated SNPs assayed on the Illumina Quad 610/660W chip. Step-down permutation
methods were used to adjust for multiple testing in all analyses. Results. Ninety-five and 62 patients with HCV chronic infection
or spontaneous clearance, respectively, were included for analysis. HLA-DQB1 (𝑝 = 1.76 ∗ 10−5) and IL-6 (𝑝 = 0.0007) genes
were significantly associated with spontaneous HCV clearance. IL-28Bwas not significantly associated with spontaneous clearance
(𝑝 = 0.17). Conclusion. Our whole-gene analytic strategy identified a previously unreported association of IL-6 with spontaneous
clearance of HCV infection. We also confirmed the finding that HLA-DQB1 is associated with spontaneous resolution of HCV
infection.
1. Introduction
The hepatitis C virus (HCV) is a flavivirus which primarily
affects the liver, with a seroprevalence of over 185 million
infections worldwide [1]. Approximately 70% of people
infected with HCV develop chronic infection and 30% are
known to spontaneously clear the infection; however these
rates vary by ancestry, gender, and other factors [2–4].
Chronic infection with HCV results in hepatic inflammation,
necrofibrosis, and may ultimately cause cirrhosis, hepatocel-
lular carcinoma, and death due to liver failure [3]. Factors that
lead to spontaneous clearance may provide important insight
into disease pathogenesis and may be important for future
assessments of prognosis as well as guiding discovery of novel
therapies.
It has been shown that mutations that alter the expression
of certain antiviral cytokines are predictive of HCV treatment
response and disease prognosis and therefore may also be
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instrumental in the biology of spontaneous clearance. Single-
nucleotide polymorphisms (SNPs) rs12979860 and rs8099917,
which are upstream of interleukin 28B (IL-28B, also known
as interferon-𝜆3) and in strong linkage disequilibrium (LD)
with each other, have been implicated as predictors of
treatment response in separate studies [5–7]. These findings
were confirmed with candidate gene studies and genotyping
currently can be used clinically to advise patients on the like-
lihood of success prior to interferon-based HCV treatment
[5].
Polymorphisms may also affect cell-mediated immune
responses in part due to their effect on viral antigen presenta-
tion via HLA class II molecules. A specificHLA class II allele
𝐷𝑄𝐵
∗0301 was found by de Rueda et al. in a candidate gene
analysis of samples from 428 treated HCV infected patients
to correlate significantly with favorable treatment response
via candidate gene analysis [8].This suggests thatHLA-DQB1
is important for presentation of HCV antigens and resulting
clearance of virus.
A recent genome-wide association study (GWAS) on a
multicohort sample of 919 HCV spontaneous clearers and
1,482 patients with persistent infection identified genome-
wide significant associationswith rs12979860 in the promoter
region of IL-28B and rs4272729 adjacent to 𝐷𝑄𝐵∗0301 [9].
Together these SNPs explained 15% of the variation in HCV
resolution in a sample comprising patients with European
and African ancestry [9]. While GWAS provides an exhaus-
tive analysis of the association of individual SNPs with a
clinical outcome, it requires a large number of patients to
empower these studies and minimize type I error [8, 9]. In
addition, GWAS may not identify SNPs that may not reach
significance individually but may be found to be important
in aggregate.Whole-gene analysis is a technique for detecting
the aggregate association of SNPs on a given gene with a
clinical outcome that addresses these limitations of GWAS.
Herein, we describe our whole-gene analysis for selected
genes that are likely to be associated with HCV clearance.
2. Subjects and Methods
2.1. Ethics Statement. The study was approved by both the
Stanford University and the University of California at San
Francisco Institutional Review Boards and was conducted in
accordancewith the guidelines established by theDeclaration
of Helsinki. Written informed consent was obtained from all
patients.
2.2. Subject Recruitment and Enrollment. One hundred and
sixty patients were recruited from 3 sites in the San Francisco
Bay Area. Of these, 122 patients were enrolled at both the San
Francisco Veterans AffairsMedical Center and the University
of California at San Francisco Moffitt-Long Hospital from
July 2007 to December 2009 as part of a study of immune
responses related to hepatitis C. Patients included in the
study were those with confirmed positive HCV antibody
and sufficient DNA in extracted samples over six months,
although all patients had infection status followed over many
years. Another 38 patients were enrolled at the Veteran’s
Administration Palo Alto Health Care System between July
2007 and September 2011 as part of a cohort enrolled for
the purpose of studying HCV infected host transcriptional
responses to interferon as well as the host genomics of viral
clearance. Blood was drawn at baseline and at 12, 24, 36,
and 48 weeks after enrollment; patients fromwhom sufficient
DNA was not obtained were contacted if possible and blood
was redrawn.
2.3. Study Assays and Sample Preparation. Spontaneous
clearance was defined as patients who were HCV antibody
positive by screening EIA assay and confirmed by CHIRON
RIBA HCV 3.0 SIA (RIBA) assay, who had a negative HCV
viral load (Abbott Real time HCV assay, Abbott Diagnostics,
North Chicago, IL) in plasma without a history of HCV-
specific treatment or who had documented acute HCV
infection by antibody and/or HCV viral load testing, and
whose HCV viral load became undetectable without need for
HCV-specific treatment. Chronic HCV infection was defined
as those patients with a positive HCV antibody and positive
HCV viral load result. HCV genotype was determined using
the Versant INNO-LiPA HCV II line probe assay (Siemens
Diagnostics, Tarrytown, NY) according to themanufacturer’s
recommendations. HIV-1 antibody testing was performed
using a screening HIV1/HIV2 EIA and confirmatory western
blot assay.This studywas approved by the StanfordUniversity
and theUniversity of California at San Francisco Institutional
Review Boards.
Blood samples were collected in cell preparation tubes
(CPT) (Becton Dickinson, Franklin Lakes, NJ) and periph-
eral blood mononuclear cells (PBMC) were separated from
whole blood according to the manufacturer’s instructions,
washed with PBS twice, and stored in freezing medium
(10% dimethyl sulfoxide (DMSO)/90% fetal bovine serum
(FBS)) or as dry pellets at −80∘C. Cell DNA was purified
from PBMC using the Qiagen kit systems (Qiagen, Valencia,
CA). DNA purity was checked and any DNA samples with
a 260/280 ratio of <1.7 were repurified. DNA amounts were
standardized with PicoGreen.
Genotyping was performed using the Illumina
Human610-Quad array (samples analyzed prior to 2011)
or the Illumina Human660W-Quad array (Illumina, San
Diego, CA) on an Illumina BeadStation system, with
GoldenGate Genotyping and Infinium Whole-Genome
Amplification procedures. Only SNPs evaluated on both
chips were included in the final analysis. Each array had
several sample-dependent and sample-independent internal
controls which were monitored with the BeadStudio
Genotyping Module Integrated Controls Dashboard. Initial
analyses of data and data quality were accomplished with the
BeadStudio software.
2.4. CandidateGene Selection. Due to sample size limitations,
we carried out a primary analysis of candidate genes. We
performed a detailed literature analysis and identified 67
host genes known or hypothesized to be integral both to the
host immune response and to the life cycle of HCV. This
included genes involved in cell-to-cell signaling, both innate
and adaptive immune responses including interferon effector
genes involved with the Janus Kinase-Signal Transducer
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Table 1: Candidate genes selection.
Candidate genes associated with HCV spontaneous clearance or response to therapy
Gene symbol Chromosomelocation Gene name
Number of SNPs in
analysis
IL28B 19q13.13 Interleukin 28B (encoding IFN-gamma-3) 4
SOCS3 17q25.3 Suppressor of cytokine signaling 3 16
SOCS1 16p13.13 Suppressor of cytokine signaling 1 2
IL-10 1q31-q32 Interleukin 10 15
IL-18 11q22.2-q22.3 Interleukin 18 6
TNF-alpha 6p21.3 Tumor necrosis factor alpha 1
TGF-beta-1 19q13.1 Transforming growth factor, beta 1 4
IL-6 7p21 Interleukin 6 42
CTLA-4 2q33 Cytotoxic T-lymphocyte-associated protein 4 7
IFNG 12q14 Interferon, gamma 8
HLA genes:
HLA-DRB1 6p21.3 Major histocompatibility complex, class II, DR beta 1 5
HLA-DQB1 6p21.3 Major histocompatibility complex, class II, DQ beta 1 40
and Activator of Transcription (JAK-STAT) pathway, major
histocompatibility complex mediated antigen presentation,
and facilitation of HCV entry into cells. The initial list was
further reduced to twelve candidates that were determined
to have the most evidence supporting their role in HCV
clearance, either spontaneous or treatment-related (Table 1).
A single overall test of each candidate gene was based on
all available SNPs either within the coding region of the
gene of interest or within the region of the next single 3󸀠 or
5󸀠 flanking/adjacent gene included on the array as defined
by the array manufacturer (Illumina) based on the available
literature at the time of production.
Rs12979860 was identified in the literature as a SNP of
special interest. However, it was only assayed on the Illumina
Human610-Quad array.Therefore, for the 32 samples assayed
with the IlluminaHuman660W-Quad array, a separate allelic
discriminationRT-PCR assaywas performed for rs129798690
as described by Tillmann et al., with results included in our
analysis [10].
2.5. Statistical Analysis. Primary analyses focused on whole-
gene tests of 12 preselected genes of interest as described
above to reduce the impact of required multiple testing
corrections on power, given the small sample. A genome-
wide SNP-based analysis was also performed in the event that
single SNPs in genes or regions not previously associatedwith
HCV spontaneous clearance might be detected and serve to
inform other candidate whole-gene analyses.
2.6. Data Preprocessing. Approximately 610–660K SNP
markers were genotyped in a genome-wide scan. SNPs
were excluded from the analysis if they had a call rate
of <0.85, a minor allele frequency <0.01, or a Hardy-
Weinberg equilibrium 𝑝 value < 0.0001, leaving 150 SNPs
in the 12 candidate genes and 540,031 additional genome-
wide markers (excluding sex chromosomes), which were
designated as potential null SNPs to be used to control for
population stratification. We used the following “100, 5, 0.5”
criterion for LD pruning to derive null SNPs as follows: (1)
consider a window of 100 SNPs; (2) calculate LD between
pairs of SNPs in the window; (3) remove one of the pairs of
SNPs if the LD is greater than 0.5; and (4) shift the window
5 SNPs forward and repeat the procedure. After linkage
disequilibrium pruning, 309,470 null SNPs were identified.
These data preprocessing steps were performed using SNP &
Variation Suite version 8 (Golden Helix, Bozeman, MT) and
PLINK [11].
2.7. Population Stratification. To control for population strat-
ification, principal components analysis was used to derive
“ancestry eigenvectors” from the set of 309,470 null SNPs.
As self-identified race is not a perfect predictor of ancestry
group, we used genotype-based principal components to
adjust for population stratification. The genomic inflation
factor, calculated before and after correction for population
structure, was used to evaluate how successful the principal
components were in correcting for population structure
effects [12].
The eigenvectors were calculated using the Bioconductor
R package snpStats and the R package eigen [13–15]. Signif-
icant ancestry eigenvectors were added as covariates in the
logistic regression model of HCV clearance.
2.8. Gene-Based Analysis. An additive genetic model was
used in all analyses. For each of the 12 selected genes, a single
likelihood ratio test (LRT) compared two logistic regression
models of HCV clearance: the “full” model with all SNPs
for that gene as well as the ancestry eigenvectors included as
predictor variables and the “null” model which included the
ancestry eigenvectors as the only predictors. The whole-gene
LRT produced a single p value for each gene, representing the
total collective association of the SNPs in that gene withHCV
clearance. Whole-gene tests have the potential to increase
power by combining statistical signal across SNPs, while
reducing the number of tests for which a multiple testing
correction is needed. Many alternative gene-based methods
4 Journal of Immunology Research
of association have been proposed, especially for rare variant
data [16]. The LRT method was selected to avoid complex or
adaptive models that might require a larger sample for robust
inference.
2.9. Step-Down Permutation Procedure to Adjust for Multiple
Comparisons. To account for multiple testing of 12 separate
candidate genes, a step-down permutation procedure was
implemented as follows [17]. The clinical variables of the
157 patients (i.e., the outcome variable, covariates, such as
HIV status, and the ancestry eigenvector) were permuted
randomly with respect to their genotype data. The LRT tests
above were repeated using the permuted data yielding 12
permutation LRT p values. These p values were ordered
from smallest to largest and the permutation procedure was
repeated 10,000 times to produce a permutation distribution
of the smallest p values, the second smallest p values, and
so on. The fifth percentiles of these distributions provided
significance thresholds that were used to assess the sig-
nificance of the 12 genes based on their observed LRT p
values. The step-down procedure was applied as follows: if
a gene with the smallest p value passed its corresponding
significance threshold, it was declared significant and the next
gene (with the second smallest p value) was evaluated. If the
second gene passed its significance threshold, then it was
declared significant and the next gene was evaluated, and
so on. Once any gene did not pass its threshold, it and all
the remaining genes were declared to be nonsignificant. The
permutation step-down process provides strong control of
familywise error rate (i.e., it ensures that the probability of
more than zero false positives is 5% or less). Both stratified
and random permutations were used and the results were
compared. Stratified permutations were performed within
the ethnic strata defined by the genotype-based principal
components.
2.10. Univariate Analysis of Candidate SNPs. Each of the
150 SNPs in the candidate genes was also analyzed in a
single-SNP logistic regression model adjusted for population
stratification. To control for multiple comparisons, the step-
down permutation procedure as the one described above was
used.
2.11. Genome-Wide Scan. To perform a genome-wide asso-
ciation analysis of SNPs with HCV clearance, a single-
SNP logistic regression was performed with HCV clearance
as the outcome variable, with and without adjustment for
the population genetic structure. Benjamini and Hochberg
procedure was used to adjust the raw p values for multiple
comparisons [18].
Most analyses were performed in R [13]. SNP tools [19]
andHaploview [20] were used to create LDmaps. D󸀠 was used
as the LD measure [21].
3. Results
Of the 163 patients initially recruited, three patients (1
spontaneous resolution and 2 HCV infected) were excluded
from analysis due to insufficient DNA isolated.Three patients
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Figure 1: Population stratification via null genes.
(1 spontaneous resolution and 2HCV infected)were excluded
from analysis due to gender mismatch. Demographic and
clinical characteristics of the 157 study participants for
which data could be obtained are presented in Table 2.
Ninety-five patients (61%) had chronic infection and 62
(39%) had spontaneous resolution. Between the groups, only
self-identified race was significantly different with African-
American patients representing 13% of the spontaneous
resolution group and 37% of the chronic infection group (𝑝 =
0.01).
3.1. Population Stratification. Shown in Figure 1 is a two-
dimensional representation of data on the first two principal
components (“ancestry eigenvectors”). The first eigenvec-
tor provides a near perfect separation of Caucasian and
African-American populations, the two largest groups in
the study. When the first four principal components were
entered in the logistic regression model of chronic infection
versus spontaneous resolution, the first eigenvector was
found to be significant (p = 0.0026). The genomic infla-
tion factor was estimated to be 1.64 before correction for
population genetic structure and 1.05 after correction using
the first ancestry eigenvector. The quantile-quantile plots
of the null SNP test statistics before and after correction
for population stratification are provided in Supplemen-
tary Figure 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/6530436. The first eigenvector
was used in all subsequent analyses to adjust for population
stratification. Using additional eigenvectors did not alter the
results.
3.2. Gene-Based Analysis. Twelve candidate genes, including
150 SNP, were selected for primary analysis (Table 1).
The number of SNPs per gene ranged from 1 to 42.The left
panel of Table 3 presents the observed LRT p value for each
Journal of Immunology Research 5
Table 2: Demographic and clinical characteristics of subjects.
Total
𝑁 = 157
Spontaneous
resolution
𝑁 = 62 (39%)
Chronic infection
𝑁 = 95 (61%)
𝑝 value
(Chi-squared test unless otherwise
noted)
Age,mean (SD) [range], years 55.9 (8.2)
[25, 81]
55.7 (8.7)
[25, 77]
55.9 (7.8)
[35, 81] 0.87 (two-sample 𝑡-test)
Gender, number (%) 0.44
Male 132 (84%) 54 (87%) 78 (82%)
Female 23 (15%) 8 (13%) 15 (16%)
Trans 2 (1%) 0 2 (2%)
Ethnicity, number (%) 0.53
Not Hispanic 126 (80%) 48 (77%) 78 (82%)
Hispanic 20 (13%) 10 (16%) 10 (11%)
Mixed 6 (4%) 3 (5%) 3 (3%)
Missing 5 (3%) 1 (2%) 4 (4%)
Self-identified race, number (%) 0.01
Caucasian 84 (54%) 36 (58%) 48 (51%)
Black 43 (27%) 8 (13%) 35 (37%)
Other or mixed 14 (9%) 7 (11%) 7 (7%)
Missing 16 (10%) 11 (18%) 5 (5%)
HIV status, number (%) 0.26
Infected 42 (27%) 13 (21%) 29 (31%)
Not infected 115 (73%) 49 (79%) 66 (69%)
HCG genotype, number (%) NA
1 NA NA 67 (71%)
2 NA NA 9 (10%)
3 NA NA 11 (12%)
4 NA NA 4 (4%)
Unknown NA NA 4 (4%)
HCV treatment, number (%) NA
SVR NA NA 23 (24%)
NR NA NA 7 (7%)
Not treated NA NA 65 (68%)
NA: not available.
gene and the corresponding significance threshold used to
adjust for multiple testing.The right panel of Table 3 presents
results for a parallel analysis with HIV status included as a
covariate.The same two genes,HLA-DQB1 and IL-6, reached
statistical significance in both analyses.The same results were
obtainedwhen stratified permutationswere performedwhere
strata, defined by the first ancestry eigenvector, roughly cor-
responded to Caucasian and African-American populations.
Genotype counts and SNP frequencies for HLA-DQB1
and IL-6 are provided in Supplementary Table 1. LDmaps for
the two significant genes are presented in Figure 2 and for the
remaining genes in Supplementary Figure 2.The LDmap for
HLA-DQB1 demonstrates a high degree of disequilibrium,
which may indicate that a few SNPs in LD with the others
may be driving the observed association with the clinical
outcome. Less LD is present in IL-6 which may indicate that
several SNPs independent of each other may be driving the
association of the gene with the clinical outcome of interest
[Figure 2].
3.3. Single-SNP Analyses. We also conducted separate single-
SNP analyses similar to those above, putting only one SNP at
a time in the full model. For the 150 candidate gene SNPs, we
adjusted for population stratification and multiple testing of
150 SNPs (Supplementary Table 2). We conducted genome-
wide analyses corrected for multiple testing, both with and
without adjustment for population stratification (Figure 3).
As expected given the small sample size, no SNP reached
statistical significance in any of these analyses, given the less
powerful SNP-based testing strategy, with its stricter multiple
testing penalty.
The smallest raw p value of 1.62× 10−6 (adjusted p= 0.328)
corresponded to SNP rs2303135 on chromosome 5.
4. Discussion
Weused a statistical methodology designed for small samples
to confirm the finding of Duggal et al. demonstrating a
significant association between spontaneous resolution of
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Figure 2: Linkage disequilibrium maps of the two significant genes, measured as D󸀠.
HCV infection and the HLA-DQB1 region [9]. Their results
identified an association between HCV clearance and single
SNPs in the gene; our results demonstrate a genetic asso-
ciation that reflects a contribution from one or more SNPs
in the gene region. In addition, we identified an association
with another gene, encoding the cytokine interleukin 6 (IL-
6), which is novel [22].
IL-6 is known as a marker of host inflammatory response
and has been thought of as a mediator of innate immunity
via its receptor interactions with gp130 and resulting proin-
flammatory transcriptional activity via both the JAK/STAT
pathway and extracellular-signal-regulated kinase/mitogen-
activated protein kinase (ERK/MAPK) pathways [23]. More
recently, IL-6 has been shown to be active in cell-mediated
immunity as an effector molecule that promotes differen-
tiation of T-helper 17 (Th-17) cells which use interleukin-
17 to increase transcription of proinflammatory genes [24].
Several studies have demonstrated that serum IL-6 levels are
significantly elevated in HCV infected patients as compared
to healthy controls [25–28]. Although one study showed
significantly lower levels of IL-6 gene expression, the vast
majority of studies demonstrate significantly higher cytokine
levels in HCV patients [29]. Relatively higher IL-6 elevations
have been associated with patients with treatment failure
versus successful treatment [26, 30].
The IL-6 −174 G/C SNP (rs1800795) in the IL-6 promoter
region, although not assayed in this study, has been asso-
ciated with HCV treatment response and differential allele
expression among races [31–33]. However, controversy exists
regarding whether differential allele expression is associated
with favorable treatment response. A possible confounder
may be varying prevalence of other neighboring IL-6 pro-
motermutations (including rs1800796 and rs1800797), which
may explain differences noted between studies to date [34–
36]. Other studies suggest that the rs1800795 polymorphism
is directly correlated with HCV spontaneous clearance [22].
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Table 3: Likelihood ratio test (LRT) results comparing full models (consisting of all SNPs for the gene) and null models after controlling for
HIV infection.
Not controlling for HIV Controlling for HIV
Gene name LRT p value 5% significance threshold∗ Gene name LRT p value 5% significance threshold∗
HLA-DQB1 1.76 ∗ 10−5 0.0006 HLA-DQB1 1.84 ∗ 10−5 0.0005
IL-6 0.0007 0.0117 IL-6 0.0008 0.0110
IL-28B 0.1700 0.0347 IL28B 0.1600 0.0324
IL-10 0.1987 0.0697 IL-10 0.2603 0.0645
CTLA-4 0.4514 0.1124 CTLA4 0.4305 0.1059
HLA-DRB1 0.4981 0.1661 HLA-DRB1 0.4759 0.1602
SOCS1 0.5313 0.2264 SOCS1 0.5071 0.2195
TNF 0.6957 0.2952 TNF 0.6508 0.2888
IFNG 0.7391 0.3755 SOCS3 0.7475 0.3675
TGF-beta-1 0.7590 0.4677 TGF-beta-1 0.8025 0.4548
SOCS3 0.7742 0.5738 IFNG 0.8027 0.5630
IL-18 0.9567 0.7027 IL-18 0.9649 0.7037
∗5% significance thresholds derived from permutation distributions (unstratified). A gene reaches statistical significance under the step-down procedure when
the observed LRT 𝑝 values for it and all more significant genes are less than their corresponding 5% thresholds.
−
lo
g
1
0
(p
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
Chr1
Chr2
Chr3
Chr4
Chr5
Chr6
Chr7
Chr8
Chr9
Chr10
Chr11
Chr12
Chr13
Chr14
Chr15
Chr16
Chr17
Chr18
Chr19
Chr20
Chr21
Chr22
Figure 3: Manhattan plot summarizing the genome-wide associa-
tion results. Smallest 𝑝 = 1.62𝑒 − 6 (adjusted 𝑝 = 0.328).
Another study has demonstrated that this SNP may be
important in autoimmune disease pathogenesis [37].
Our whole-gene analysis may have identified a previously
undetected association of IL-6 with spontaneous clearance
by testing the total combined effect of multiple SNPs which
are not in linkage disequilibrium with each other, each
with a relatively small effect, and are therefore undetectable
in a single-SNP-based test, especially when subjected to a
genome-wide multiple testing correction. Thus, it can be
possible by examining the gene as a whole to identify novel
genic associations with a clinical outcome that might elude
single-SNP analysis.
Our study is limited by the small sample, but this
limitation can be partly overcome by restricting analysis to
a preselected set of candidate genes with a priori evidence
and by testing genes rather than SNPs in order to reduce
the number of tests and increase power. Large samples
are expensive and sometimes unavailable, if few patients
meet appropriate inclusion/exclusion criteria. In fact, it is
sometimes impossible to obtain a larger sample except by
introducing greater heterogeneity into the study popula-
tion, which might sometimes reduce power to the point
of offsetting any advantage of sample size. The present
strategy may also be more successful when a gene has many
individual SNPs, each making a small contribution to the
phenotype.
Race was significantly different between the chronic
infection and spontaneous clearer groups and was missing
for 16 patients. The most common reasons for missing data
were patients listing race as Hispanic (which was coded as
an ethnicity for the purposes of this study) and not defining
any other racial category. This may have contributed to the
difference as there was more missing data in the spontaneous
clearance group. The other reason may be a true reflection
of racial differences in spontaneous clearance as prior studies
have also shown a higher rate of persistent HCV infection in
African ancestry populations [9].
Some SNPs, possibly associated with spontaneous clear-
ance in prior literature, were not included on the chip
array. Rs4272729 (in HLA-DQB1 gene region), rs1800795,
rs1800796, and rs1800797 (in IL-6 gene region) were not
included in either the Illumina 610 or 660W Quad chip used
to assay sample DNA. Although included in the analysis, IL-
28B SNPs rs12979860 and rs8099917 were not found to be
significantly associated with spontaneous viral clearance. In
addition, the IL-28B gene as a whole was not found to be
significantly associated with spontaneous clearance in this
analysis.Thismay be due to an insufficient number of patients
to demonstrate a difference, as well as the small number of
SNPs assayed, as the association of SNPs in the IL-28B region
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with viral clearance is strongly suggested in prior literature
[4–7, 9].
Understanding the immunologic host factors that predict
clearance of HCV is important in estimating treatment
prognosis for different patients. However, it may also be of
critical importance in the future for selecting antivirals for
treatment, for vaccine development, and for the development
of more potent antivirals. Additionally, understanding the
genes involved in the clearance of HCV may provide a
clearer understanding of the human immune response to
viral pathogens and disease. Ourwhole-gene analytic strategy
identified a previously unreported association of IL-6 with
spontaneous clearance of HCV infection. We also confirmed
an earlier finding that HLA-DQB1 is associated with sponta-
neous clearance.
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